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Background: The current staging system for malignant pleural 
mesothelioma (MPM) is controversial. To plan revisions of this 
system, the International Association for the Study of Lung Cancer 
Staging Committee developed an international database. Initial anal-
yses focus on patients managed surgically.
Methods: Participation was solicited from centers known to have 
MPM registries. Common data elements were analyzed by the 
International Association for the Study of Lung Cancer Staging 
Committee Statistical Center. Survival was analyzed by the Kaplan–
Meier method, prognostic factors by log rank and Cox regression 
model. p Value less than 0.05 was significant.
Results: Data included 3101 patients (15 centers, 4 continents). 
Demographics: median age 63 years, 79% men, 62.3% epithelioid 
tumor. Best tumor, node, metastasis (bTNM) stages were: I (11%), II, 
(21%), III (48%), and IV (20%). Curative-intent surgery was performed 
in 1494 patients (64.5%). Median survivals by clinical TNM and patho-
logical TNM were similar: stage I, 21 months; stage II, 19 months; stage 
III,16 months; and stage IV, 12 months. Median survival by histology: 
epithelioid 19 months, biphasic 13 months, and sarcomatoid 8 months. 
By multivariable analyses, significant differences in overall survival 
were seen for: T4 versus T3 and T3 versus T2 but not T2 versus T1; N0 
versus N1 and N2 but not N1 versus N2; stages III and IV versus I but 
not II versus I; epithelioid histology versus other; age of female versus 
age of male; and palliative versus curative-intent surgery.
Conclusions: This is the largest international database examining 
outcomes in surgically managed MPM patients. Survival differences 
reported from smaller databases are confirmed but suggest the need 
to revise tumor and node staging.
Key Words: Maligant pleural mesothelioma, Staging, Revision of 
staging system.
(J Thorac Oncol. 2012;7: 1631–1639)
Malignant pleural mesothelioma (MPM) is an uncommon and usually fatal malignancy. A well-validated and 
internationally accepted staging system is essential to evaluate 
new therapies for this difficult disease. Until the mid 1990s no 
such staging system existed. At least six staging paradigms 
had been proposed, none evidence-based, and few using a 
TNM (tumor, node, metastasis) system. In 1994, at a workshop 
sponsored by the International Association for the Study of 
Lung Cancer (IASLC) and the International Mesothelioma 
Interest Group (IMIG) MPM investigators analyzed existing 
surgical databases to develop a TNM-based staging system.1 
Subsequently, this proposed staging system was accepted by 
the UICC (International Union Against Cancer) and the AJCC 
(American Joint Commission on Cancer) as the international 
MPM staging system for the 6th and 7th editions of their 
staging manuals.2,3 The IMIG staging system has since been 
widely used in both retrospective analyses and prospective 
clinical trials. However, widespread concerns exist about 
the validity of the current MPM staging system because 
it is derived from analyses of small, retrospective surgical 
series, can be difficult to apply to clinical staging, and uses 
descriptors for lymph node involvement, which may not be 
relevant to MPM. Therefore, in collaboration with IMIG, the 
IASLC has decided to update the staging system for MPM by 
developing a large international database, an effort modeled on 
the revisions that the IASLC proposed for lung cancer staging 
for the 7th editions of the UICC and AJCC manuals.4 Here we 
report the initial analyses of the international IASLC/IMIG 
database for MPM, with the primary aim to identify areas in 
which the current staging system warrants modification.
METHODS
Data Acquisition
Participation in this database was solicited from investi-
gators active in the IASLC and/or IMIG. The initial analyses 
planned to focus on MPM patients who had surgery as part of 
Copyright © 2012 by the International Association for the Study of Lung Cancer
ISSN: 1556-0864/12/0711-1631
Initial Analysis of the International Association For the Study 
of Lung Cancer Mesothelioma Database
Valerie W. Rusch, MD,* Dorothy Giroux,† Catherine Kennedy,‡ Enrico Ruffini,§ Ayten K. Cangir,||  
David Rice,¶ Harvey Pass,# Hisao Asamura,** David Waller,†† John Edwards,†† Walter Weder,‡‡  
Hans Hoffmann,§§ Jan P. van Meerbeeck,|||| on behalf of the IASLC Staging Committee  
and participating institutions
*Memorial Sloan-Kettering Cancer Center, New York, New York; †Cancer 
Research and Biostatistics, Seattle, Washington; ‡University of Sydney, 
Strathfield Private Hospital Campus, Sydney, Australia; §University of 
Torino, Ospedale San Giovanni Battista, Torino, Italy; ‖Ankara University 
Faculty of Medicine, Ankara, Turkey; ¶M.D. Anderson Cancer Center, 
Houston, Texas; #NYU School of Medicine, New York, New York; 
**National Cancer Center Hospital, Tokyo, Japan; ††Glenfield Hospital, 
Leicester, United Kingdom; ‡‡University Hospital, Zurich, Switzerland; 
§§Thoraxklinik, University of Heidelberg, Heidelberg, Germany; and 
‖‖University Hospital, Ghent, Belgium.
Disclosure: The authors declare no conflict of interest.
Address for correspondence:Valerie W. Rusch, MD, Chief, Thoracic Service, 
Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 
York Avenue, New York, NY 10065. E-mail: ruschv@mskcc.org
Journal of Thoracic Oncology
7
11
© 2012 by the International Association for the Study of Lung Cancer
1556-0864
JTO
202220
Initial Analysis of IASLC Mesothelioma Database
Rusch et al.
2012
November
1631
1639
10.1097/JTO.0b013e31826915f1
Anjana
J Thorac Oncol
ORIGINAL ARTICLE
1632 Copyright © 2012 by the International Association for the Study of Lung Cancer
Rusch et al. Journal of Thoracic Oncology  •  Volume 7, Number 11, November 2012
their care and therefore, presumably had earlier-stage disease 
and better performance status than patients managed non-
surgically. All data were retrospective, and by mutual agree-
ment were transmitted to Cancer Research and Biostatistics in 
Seattle, Washington, as coded data without identifiable private 
information, with appropriate regulatory permission from the 
contributing sites. Common data elements were established 
after review of each institutional database at Cancer Research 
and Biostatistics. The timeframe chosen for data was from 
1995 to 2009, which was considered a contemporary period 
providing information relevant to potential revisions of the 
MPM staging system.
Surgical procedures were classified as operations per-
formed with either palliative or curative intent. The former 
included exploration, no resection, and palliative (i.e., partial) 
pleurectomy whereas the latter included extrapleural pneumo-
nectomy (EPP), pleurectomy/decortication (P/D) for resection 
of all gross tumors, and P/D combined with anatomical lung 
resection other than pneumonectomy. Because of the diverse 
nature of the individual databases and the fact that they were 
amalgamated retrospectively, details of chemotherapy and 
radiation administered were not available and were thus sim-
ply recorded as modalities given or not given.
Statistical Methods
Survival was measured from the date of pathologic 
diagnosis to the date of last contact or death resulting from 
any cause. Median survival was estimated using the Kaplan–
Meier regression method. Prognostic groups were assessed by 
Cox regression analysis of survival, using the SAS system for 
Windows version 9.2 PHREG method. Significance values 
from pairwise comparisons reflect the Wald test; those from 
joint model effects (e.g., comparing the full model to the null 
model) reflect the likelihood ratio test.
All covariates in regression analyses were modeled 
categorically using indicator variables, and the threshold for 
statistical significance was set at a p value of 0.05. Age was 
classified into three categories, with cutpoints at 50 and 65 
years chosen based on graphical analysis of the data. The cut-
points at 50 and 65 years were confirmed as optimal split points 
(after rounding age to the nearest 5-year mark) by analysis 
of running log rank statistics. Covariates that met the criteria 
for statistical significance by univariate analysis were further 
evaluated for inclusion in multivariable regression models, 
using a stepwise algorithm with backward selection. Such 
models were considered exploratory in nature when 33% or 
more of the sample had to be excluded from analysis because 
of missing data for any of the covariates being explored.
Stage-related differences in the context of surgery with 
curative intent were identified a priori as of particular inter-
est. Thus, type of operation (curative versus palliative) was 
included as a covariate in all analyses, and patterns were fur-
ther explored in the subset of patients treated by surgery with 
curative intent.
RESULTS
Patient and tumor demographics are shown in Table 1. 
Data were submitted on 3101 patients from 15 centers in 
four continents, with 82.6% of the patients being from North 
America and Europe. Patients were predominantly men with 
a median age of 63 years. Asbestos exposure was recorded 
in nearly half the patients but data on this were lacking in 
30.9% of the cases. Epithelioid histology was the most com-
mon MPM subtype reported and was seen in more than 60% 
of cases. Because of the heterogeneity of the individual data-
bases, both clinical and pathological staging information was 
not available on all patients and thus clinical (cTNM) and 
pathological (pTNM) staging information were combined in 
2316 patients to provide best staging (bTNM) in accordance 
with AJCC and UICC guidelines. Table 2 shows the surgical 
procedures performed. The majority of patients (64.5%) had 
curative-intent procedures with approximately half undergo-
ing EPP.
Figure 1 shows the differences between clinical (cTNM) 
and pTNM staging in the 1056 patients for which such 
TABLE 1. Patient Demographics
Source No. of 
Patients
Percentage 
Total %
United States of America 1151 37.1
Italy 549 17.7
Australia 392 12.6
Turkey 236 7.6
Japan 180 5.8
Great Britain 177 5.7
Switzerland 158 5.1
Germany 97 3.1
Canada 82 2.6
EORTC (Europe) 59 1.9
France 20 0.6
Age (yrs)
< 40 83 2.7 Min 13
Max 94
Mean 62.1
Median 63
40–60 1098 35.4
60–80 1807 58.3
≥80 or older 110 3.5
No data 3 0.1
Sex
Female 621 20.0
Male 2451 79.0
No data 1 0.0
Histology
Biphasic 483 15.6
Epithelial 1933 62.3
Sarcomatoid 253 8.2
Other mesothelioma/NOS 432 13.9
Asbestos exposure
No 558 18.0
Probable 91 2.9
Yes 1495 48.2
No data 957 30.9
EORTC, European Organisation for Research and Treatment of Cancer; NOS, not 
otherwise specified.
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information was available. Upstaging based on final pTNM 
occurred in up to 80% of the patients considered to have 
cTNM stage I or II disease but only in 22.8% of the cTNM 
stage III tumors and not at all in stage IV disease.
More than 90% of the patients were followed until death 
or for a minimum of 1 year, and the median length of follow-
up for all patients was 15 months. Survival cTNM, pTNM, and 
bTNM stages for all patients undergoing any type of surgi-
cal procedure are shown in Figure 2. Although these survival 
curves show separation by stage, the differences in median 
survival are least apparent between stages I and II. Overall sur-
vival by bTNM for the patients undergoing surgery with cura-
tive intent is shown in Figure 3 and demonstrates more obvious 
differences in median survival across all four tumor stages.
Survival by tumor T categories for all patients having 
nonmetastatic disease managed by any type of surgical 
procedure and for those undergoing operations with curative 
intent is shown in Figure 4. Separation is seen among the 
median survivals for all four T categories but this is least 
apparent between T2 and T3. Survivals by tumor N categories 
for patients undergoing any type of surgical procedure and for 
those having curative-intent operations are shown in Figure 5. 
Differences are seen for N0 versus N1 versus N2 but with the 
FIGURE 1. Differences between clinical and pathological 
staging in the 1056 patients for whom such information was 
available.
FIGURE 3. Overall survival by best staging for patients 
undergoing surgery with curative intent. The 95% confidence 
interval is shown in parentheses.
FIGURE 2. Survival for all patients undergoing any type of 
surgical procedure, according to clinical staging, pathologica 
staging, and best staging. The 95% confidence interval is 
shown in parentheses.
TABLE 2. Information on Surgical Procedures Performed 
for all 3101 Submitted Cases That Met Initial Screening 
Requirements for Date of Diagnosis, Date of Last Follow-Up 
and Age
Procedure Total Staged Cases  
(Percentage Total, %)
Surgery—palliative 1250 729 (31.5)
 Exploration 1172 669 (28.9)
 Palliative pleurectomy 78 60 (2.6)
Surgery—curative 1708 1494 (64.5)
 Pleurectomy/decortication 479 299 (12.9)
 Extrapleural pneumonectomy 1225 1191 (51.4)
 Therapeutic lunga 4 4 (0.2)
No surgery 84 70 (3.0)
No data 59 20 (0.9)
Total 3101 2316
aCases in which lung resection other than pneumonectomy with or without chest-
wall resection was performed with curative intent.
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predominant difference being between N0 and N1/N2. Data on 
the number of lymph nodes showing metastatic disease were 
available in only 181 patients. In this small patient cohort, no 
difference in survival was seen according to the number of 
involved nodes (data not shown).
The relationship between histological subtype and 
survival for all patients undergoing surgery is shown in 
Figure 6. Whether tumors were classified according to cTNM, 
pTNM, or bTNM stage, marked differences in outcome are 
seen with epithelioid histology being associated with the best 
outcome, and sarcomatoid, the worst. The 337 tumors reported 
as MPM not otherwise specified were associated with a sur-
vival virtually identical to that of tumors of biphasic histology 
(data not shown).
Survival was significantly different according to 
whether the surgical procedure was performed with curative 
FIGURE 4.  Survival by tumor T stage for (A) all patients with 
nonmetastatic disease having any type of surgical procedure, 
(B) those undergoing operations with curative intent. The 
95% confidence interval is shown in parentheses.
FIGURE 5. Survival by tumor N stage for patients under-
going any type of surgical procedure and for those having 
curative-intent operations. The 95% confidence interval is 
shown in parentheses.
FIGURE 6. The relationship between histological subtype 
and survival according to clinical staging, pathological stag-
ing, and best staging for all patients undergoing surgery. The 
95% confidence interval is shown in parentheses.
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versus palliative intent (median survival 18 versus 12 months, 
p < 0.0001; Fig. 7). Prognostic groups defined by the type of 
curative-intent procedure performed (EPP versus P/D) were 
examined in relationship to tumor stage (Fig. 8). Stage I tumors 
resected by EPP were associated with a median survival of 40 
months whereas those managed by P/D had a median survival 
of 23 months. No differences in survival between EPP and 
P/D were identified in patients with higher-stage disease.
Among the patients undergoing curative-intent opera-
tions, 1162 received additional treatment, either chemotherapy 
or radiation or both. Relative to the 207 patients in this group 
who were managed with surgical resection alone (Fig. 9), the 
patients receiving multimodality treatment had a significantly 
better outcome with median survivals of 20 versus 11 months 
(p < 0.0001).
Several multivariable analyses (Tables 3 and 4) were per-
formed for patients undergoing any type of surgical procedure. 
Overall tumor stage (p < 0.0001), T category (p < 0.0001), N 
category (p < 0.0001), tumor histology (p < 0.0001), patient 
sex (p = 0.0002) and age (p = 0.0025), and type of operation 
(curative versus palliative, p < 0.0001) had a statistically sig-
nificant impact on survival. Likewise, pairwise comparisons 
of adjacent stage groups and T and N categories yielded statis-
tically significant differences in survival, with the exception of 
stages I versus II, T1 versus T2, and N1 versus N2.
DISCUSSION
During the past 20 years, improvements in surgical 
management, chemotherapy, and radiotherapy have led to an 
increasing use of multimodality therapy and to more clinical 
trials in MPM.5–11 A clinically and pathologically accurate 
staging system is essential to selecting patients for treatment 
and to assessing the benefit of new therapies. The current 
MPM staging system and subsequent reports suggesting pos-
sible revisions are based on analyses of surgical series that 
were generally single institution, retrospective, and small in 
numbers.12–18 This IASLC database, though retrospective, is 
the largest, multicenter, and international database in MPM 
to date.
FIGURE 7. Survival in relation to the type of surgical proce-
dure performed (curative versus palliative intent). The 95% 
confidence interval is shown in parentheses.
FIGURE 8.  Survivals according to type of curative-intent pro-
cedure (EPP or P/D) and stage. A, stage I–II and (B) stage III–IV. 
The 95% confidence interval is shown in parentheses. EPP, 
extrapleural pneumonectomy; P/D, pleurectomy/decortication.
FIGURE 9.  Survival for patients managed with curative-intent 
surgery only versus those managed with multimodality therapy. 
The 95% confidence interval is shown in parentheses.
TABLE 3.  Cox Regression Model of Survival, Including Best 
Stage, Histology, Sex, and Age (n = 2107)
Variable Hazard Ratio p
II vs. I 1.16 0.1153
III vs. I 1.47 <.0001
III vs. II 1.27 0.0002
IV vs. I 1.86 <.0001
IV vs. III 1.26 0.0008
Other histology vs. epithelial 1.70 <.0001
Male vs. female 1.28 0.0002
Age, yrs
50–45 vs. <50 1.23 0.0058
65+ vs. <50 1.31 0.0006
65+ vs. 50–64 1.07 0.2500
Palliative vs. curative surgery 1.71 <.0001
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Our analyses not only indicate that the current staging 
system by and large appropriately distinguishes among T and N 
categories and overall stages but also highlight areas for poten-
tial revision. Differences in survival among T categories and 
overall stage classifications are most apparent among patients 
undergoing resection with curative intent. Unlike lung cancer 
in which the size and location of the primary tumor can be 
reproducibly measured, the extent of the tumor in MPM is not 
easily measured. The current T descriptors are qualitative and 
most applicable to pathological staging. Conceivably, in the 
future, volumetric tumor measurement on computed tomog-
raphy could replace the current T descriptors.19–24 However, 
this will require additional validation studies of this approach 
and widespread commercial availability of computed tomog-
raphy software for automated volumetric measurements. For 
immediate purposes, revision of the descriptors for early-
stage disease (T1–3) may be appropriate based on information 
regarding the clinically available anatomical extent of disease. 
For these initial analyses, few of the participating institutions 
were able to provide information about the precise anatomi-
cal extent of tumor leading to the assignment of T categories 
(e.g., scattered tumor nodules versus confluent pleural tumor, 
or presence or absence of chest wall invasion). This informa-
tion will be necessary to recommend definitive revision of T 
categories. Our data also highlight the discrepancy between 
cTNM and pTNM staging, especially in early-stage disease 
and emphasize the need to develop standardized algorithms 
that provide the most accurate and cost-effective approaches 
to precise clinical staging.25
The application of lung cancer N categories to MPM in 
the original IMIG staging system was empiric because no data 
were available at the time to suggest alternatives. The group-
ing of both N1 and N2 disease into stage III disease was also 
empiric because all that was known at the time was that any 
lymph node involvement had an adverse impact on overall 
survival. Subsequent analyses of various surgical series sug-
gested that the preferential pattern of lymphatic drainage in 
MPM is N2 lymph nodes including some mediastinal regions 
such as peridiaphragmatic and internal mammary lymph 
nodes, which are not usually involved in lung cancers.16,26–28 
These analyses have also suggested that the involvement of 
only N1 lymph nodes was associated with a better survival 
and that of multiple N2 lymph node stations, with a worse 
survival.16 In univariate analysis, our data suggest a difference 
in survival for N1 versus N2 disease (Fig. 5) but these differ-
ences are not significant in multivariable analyses (Table 4). 
More detailed information about the extent of lymph node 
involvement will be needed from participating institutions to 
resolve this issue.
Stage groupings, especially for stages I and II disease, 
also need to be reassessed. Univariate analyses of this database 
(Figs. 2 and 3) suggest that the current stage groupings 
identify patient groups with distinctly different survivals. 
It would seem that the current staging system satisfies the 
requirement of TNM stage stratification based solely on 
anatomical definitions. Future analyses with more detailed 
information about T and N categories (as noted above) may 
alter stage groupings or lead to classification of stages I and 
II into a and b subcategories. It is also of some concern that 
multivariable analyses (Table 3) taking into account known 
significant prognostic factors do not show a significant 
difference between stages I and II. Future analyses with more 
detailed information about T and N categories (as noted 
above) should readdress this issue because it is important that 
stage groupings be applicable across histological subtypes and 
patient age and sex. Although the differences among stages 
II, III, and IV remain significant in these analyses, stages III 
and IV define broad categories of disease including locally 
advanced tumors (T3 and T4), regionally advanced disease 
(N1 and N2), and metastatic disease (M1). In the future, the 
addition of a larger group of patients with more advanced 
disease, staged clinically and managed nonsurgically may 
help determine whether stages III and IV should be classified 
into a and b subcategories.
The primary purpose of this database is to determine 
whether and how the current TNM staging system should be 
revised. Given retrospective data, heterogeneous data sources, 
and individualized treatment selection, evaluation of the effect 
of clinical interventions on survival can only be considered 
exploratory and hypothesis generating. Other studies, both ret-
rospective and prospective, have suggested a beneficial effect 
of both curative-intent surgery and multimodality treatment on 
survival.8,10,29–32 Our data (Table 3 and Fig. 9), absent details of 
adjuvant chemotherapy and radiotherapy, are consistent with 
previous reports in this regard. The role of EPP versus P/D 
remains highly controversial with impassioned views for and 
against the use of EPP.33–44 A recent small, multicenter trial 
reported no survival benefit for patients undergoing EPP.45 
However, this trial and its analyses were severely criticized by 
TABLE 4.  Cox Regression Model of Survival, Including T and 
N Stage, Intent of Surgery, Histology, and Sex (n = 1972)
Any Surgical Procedure
Variable Hazard Ratio p
T2 vs. T1 1.16 0.0907
T3 vs. T1 1.32 0.0011
T4 vs. T1 1.66 < 0.0001
N1 vs. N0 1.26 0.0071
N2 vs. N0 1.40 < 0.0001
Other histology vs. epithelial 1.70 < 0.0001
Male vs. female 1.25 0.001
Age, yrs
50–45 vs. <50 1.16 0.0483
65+ vs. <50 1.24 0.008
Palliative vs. curative 1.77 < 0.0001
Additional Pairwise Comparisons
Comparison
T2 vs. T1 1.16 0.0907
T3 vs. T2 1.14 0.0319
T4 vs. T3 1.26 0.0035
N1 vs. N0 1.26 0.0071
N2 vs. N1 1.11 0.2771
Age 65+ vs. 50–64 yrs 1.06 0.2769
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other investigators because it was not originally designed to 
assess the survival benefit of EPP, included a small number 
of patients, and reported an operative mortality substantially 
higher than that of any other contemporary series.46 Thus the 
use of EPP versus P/D in MPM remains an open question. 
For the stage I patients in our data set, those treated with EPP 
survived longer than other patients did (Fig. 8). Why the EPP 
patients survived longer—because of superior intervention, 
better overall risk profile, or other considerations specific 
to the institution or region—cannot be determined without 
some understanding of how treatment was selected for these 
patients. Within the individual centers that contributed to this 
database, stage I disease was generally managed exclusively 
by EPP to the exclusion of P/D, or vice versa. As with lung 
cancer, different surgical procedures may be appropriate for 
different groups of patients having MPM. It is perhaps time 
to study this question prospectively with more restricted-stage 
and prognostic-factor eligibility than has been done in the past.
In summary, analyses of this database, the largest inter-
national one to date, suggest that the current MPM staging sys-
tem does generally classify patients into groups with distinctly 
different outcomes but also highlights areas for potential revi-
sion. As IASLC and IMIG investigators continue to expand the 
database, more detailed information on T and N descriptors is 
needed; so is the addition of patients staged clinically and man-
aged nonsurgically required to propose revisions. Analyses of 
prognostic factors are also an important aspect of this database 
and are the subject of a separate article.
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